Cardinal (CAH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Forte Biosciences (FBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Looking for broad exposure to the Healthcare - Broad segment of the equity market? You should consider the First Trust Health Care AlphaDEX ETF (FXH), a passively managed exchange traded fund launched ...

Burlington Stores, Inc. BURL is currently trading at a low price-to-sales (P/S) multiple, which is below the average of the Zacks Retail-Discount Stores industry and Retail-Wholesale sector. With a ...

Tuesday saw the event that a good chunk of the tech world anticipates every March and November when the founder and CEO of NVIDIA, Jensen Huang, takes the stage for his power-packed keynote. The ...

Chicago, IL – March 6, 2025 – Today, Zacks Equity Research Equity arePhillips 66 PSX, Marathon Petroleum MPC, Valero Energy VLO and Galp Energia GLPEY. Industry ...